Androgen therapy and atherosclerotic cardiovascular disease.

DSpace/Manakin Repository

Search OPUS


Advanced Search

Browse

My Account

Show simple item record

dc.contributor.author McGrath, KC
dc.contributor.author McRobb, LS
dc.contributor.author Heather, AK
dc.date.accessioned 2012-02-10T06:08:58Z
dc.date.issued 2008
dc.identifier.citation Vascular health and risk management, 2008, 4 (1), pp. 11 - 21
dc.identifier.issn 1176-6344
dc.identifier.other C1UNSUBMIT en_US
dc.identifier.uri http://hdl.handle.net/10453/16878
dc.description.abstract Cardiovascular disease (CVD) remains the leading cause of death in Western society today. There is a striking gender difference in CVD with men predisposed to earlier onset and more severe disease. Following the recent reevaluation and ongoing debate regarding the estrogen protection hypothesis, and given that androgen use and abuse is increasing in our society, the alternate view that androgens may promote CVD in men is assuming increasing importance. Whether androgens adversely affect CVD in either men or women remains a contentious issue within both the cardiovascular and endocrinological fraternities. This review draws from basic science, animal and clinical studies to outline our current understanding regarding androgen effects on atherosclerosis, the major CVD, and asks where future directions of atherosclerosis-related androgen research may lie.
dc.format Print
dc.language eng
dc.relation.isbasedon 10.2147/vhrm.2008.04.01.11
dc.subject Animals, Humans, Arteriosclerosis, Cardiovascular Diseases, Androgens, Clinical Trials as Topic, Risk Factors, Androgens, Animals, Arteriosclerosis, Cardiovascular Diseases, Clinical Trials as Topic, Humans, Risk Factors, NA, Cardiovascular System & Hematology
dc.subject Animals; Humans; Arteriosclerosis; Cardiovascular Diseases; Androgens; Clinical Trials as Topic; Risk Factors; Androgens; Animals; Arteriosclerosis; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Risk Factors; NA; Cardiovascular System & Hematology
dc.title Androgen therapy and atherosclerotic cardiovascular disease.
dc.type Journal Article
dc.parent Vascular health and risk management
dc.journal.volume 1
dc.journal.volume 4
dc.journal.number 1 en_US
dc.publocation United Kingdom en_US
dc.identifier.startpage 11 en_US
dc.identifier.endpage 21 en_US
dc.cauo.name SCI.Medical and Molecular Biosciences en_US
dc.conference Verified OK en_US
dc.for 1103 Clinical Sciences
dc.personcode 111077 en_US
dc.personcode 0000065911 en_US
dc.personcode 108123 en_US
dc.percentage 100 en_US
dc.classification.name Clinical Sciences en_US
dc.classification.type FOR-08 en_US
dc.edition en_US
dc.custom en_US
dc.date.activity en_US
dc.location.activity en_US
dc.description.keywords NA en_US
dc.description.keywords NA
dc.description.keywords NA
dc.description.keywords NA
dc.description.keywords Animals
dc.description.keywords Humans
dc.description.keywords Arteriosclerosis
dc.description.keywords Cardiovascular Diseases
dc.description.keywords Androgens
dc.description.keywords Clinical Trials as Topic
dc.description.keywords Risk Factors
dc.staffid 108123 en_US
pubs.embargo.period Not known
pubs.organisational-group /University of Technology Sydney
pubs.organisational-group /University of Technology Sydney/Faculty of Science
pubs.organisational-group /University of Technology Sydney/Faculty of Science/School of Medical and Molecular Sciences
pubs.organisational-group /University of Technology Sydney/Strength - Health Technologies


Files in this item

This item appears in the following Collection(s)

Show simple item record